Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007002571) USE OF AN ANTI C5 COMPLEMENT ANTIBODY TO TREAT PATIENTS WITH SICKLE CELL DISEASE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/002571 International Application No.: PCT/US2006/024770
Publication Date: 04.01.2007 International Filing Date: 23.06.2006
IPC:
A61K 39/395 (2006.01) ,A61P 7/06 (2006.01) ,C07K 16/18 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
06
Antianaemics
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
Applicants:
ALEXION PHARMACEUTICALS, INC. [US/US]; 352 Knotter Drive Cheshire, CT 06410, US (AllExceptUS)
ROTHER, Russell [US/US]; US (UsOnly)
Inventors:
ROTHER, Russell; US
Agent:
VARMA, Anita ; Fish & Neave IP Group Ropes & Gray LLP One International Place Boston, MA 02110-2624, US
Priority Data:
60/693,47323.06.2005US
Title (EN) USE OF AN ANTI C5 COMPLEMENT ANTIBODY TO TREAT PATIENTS WITH SICKLE CELL DISEASE
(FR) UTILISATION D'UN INHIBITEUR DU COMPLEMENT POUR TRAITER DES PATIENTS ATTEINT DE DREPANOCYTOSE
Abstract:
(EN) A method of treating a sickle cell patient with an anti C5 complement antibody is disclosed. Treatment with said antibody decreases the extent of red blood cell lysis and decreases the consequential clinical sequelae.
(FR) L'invention concerne un procédé servant à traiter un patient atteint de drépanocytose au moyen d'un inhibiteur du complément. Le traitement au moyen d'un inhibiteur de l'activation du complément diminue l'étendue de la lyse des globules rouges et réduit les séquelles cliniques résultantes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)